AURAHealthcare · BiotechnologyThe 6 Wall Street analysts covering Aura Biosciences, Inc. hold a median 12-month price target of $15 — +138.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 22 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Aura Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (72): The share price has been relatively steady.
Revisions (28): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +138.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $18 |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $22 → $24 |
| 30 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Nov 2025 | Evercore ISI Group | Reinstates | Outperform | $13 |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 May 2025 | HC Wainwright & Co. | Assumes | Buy | $22 |
| 23 May 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 26 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 26 Mar 2025 | JMP Securities | Maintains | Market Outperform | — |
| 25 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | JMP Securities | Maintains | Market Outperform | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Oct 2024 | BTIG | Maintains | Buy | — |
| 18 Oct 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Oct 2024 | Scotiabank | Maintains | Sector Outperform | — |
| 13 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Sept 2024 | JMP Securities | Maintains | Market Outperform | — |
| 28 Aug 2024 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AURA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Aura Biosciences, Inc. returned +10.9% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 41% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aura Biosciences, Inc. has a market value of $669.9M and an enterprise value of $362.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$131.0M.
Free cash flow in the twelve months to 30 June 2026: −$103.4M.
Trailing P/E: −3.7×; forward P/E: −3.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aura Biosciences, Inc. employs 113 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aura Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aura Biosciences presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the session published on Seeking Alpha.
Why it matters — The presentation gives AURA watchers insight into the company's positioning and messaging at a major healthcare investor conference.
Aura Biosciences announced that CEO and President Natalie Holles will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026. The announcement was made via GlobeNewsWire on September 2, 2026.
Why it matters — AURA watchers may be interested as the CEO's participation at a major investor conference offers a platform for the company to present its clinical-stage ocular cancer therapy to the investment community.
Aura Biosciences announced on September 1, 2026 that it granted inducement equity awards to three newly appointed executives — Erica Kratz (Chief Regulatory and Quality Officer), Susan Abu-Absi (Chief Operating Officer), and Julie Person (Chief People Officer). The awards were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — Aura watchers would care because this reflects the addition of three new C-suite leaders and associated equity compensation, which is standard corporate governance news for the company.
Aura Biosciences is advancing Bel-sar for early choroidal melanoma, with the Phase 3 CoMpass trial fully enrolled and topline data expected in the second half of 2027. Phase 2 data showed 80% tumor control and a strong safety profile, and the company recently completed a C-suite overhaul and a $299 million capital raise, with funding expected to last into 2029.
Why it matters — AURA watchers would care because the streamlined management and extended cash runway position the company to reach its pivotal Phase 3 readout for Bel-sar, a potential first-in-class treatment in a field with significant unmet need.
The 6 Wall Street analysts covering Aura Biosciences, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Aura Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aura Biosciences, Inc. 42 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Aura Biosciences, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (72 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +138.1% from the last close, and Ticker Nerd's factor model ranks Aura Biosciences, Inc. 42 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aura Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $23 over the next 12 months.
Aura Biosciences, Inc. returned +10.9% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers.
The most recent item we track (Seeking Alpha, 16 Sept 2026): "Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Aura Biosciences presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the session published on Seeking Alpha.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function. The company’s platform is built around virus-like particles that deliver therapeutic payloads directly to tumors and support an immune response against cancer. Aura Biosciences is advancing its oncology pipeline across ocular oncology and other related indications, including bladder cancer, using a targeted approach intended for specialist treatment settings. Headquartered in Boston, Massachusetts, Aura Biosciences plays a focused role in the biotechnology market as a developer of novel cancer therapies for hard-to-treat solid tumors.
CEO Ms. Natalie C. Holles · 113 employees · United States · https://www.aurabiosciences.com
